Impact of coronavirus infection on cognitive functions in elderly patients


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper reviews information on the etiology and pathogenesis of neurological manifestations in patients who have had coronavirus infection (COVID-19). It presents the data of studies that have shown that cognitive impairment is the long-term consequences of the central nervous system. Elderly patients are more susceptible to neuropsychiatric and cognitive impairment in COVID-19, and in the case of pre-existing cognitive impairment and dementia after a coronavirus infection; they are observed to have a progression of these disorders. Early detection of neuropsychological manifestations in persons who have experienced COVID-19 can lower the risk of subsequent irreversible disorders and further neurocognitive decline. Nootropic, metabolic, and antioxidant agents with a neuroprotective effect can be recommended for correction of cognitive impairment in elderly patients.

Full Text

Restricted Access

About the authors

T. V Potupchik

V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Email: potupchik_tatyana@mail.ru

L. S Evert

Research Institute for Medical Problems of the North, Krasnoyarsk Research Center, Siberian Branch, Russian Academy of Sciences

Yu. R Kostyuchenko

Research Institute for Medical Problems of the North, Krasnoyarsk Research Center, Siberian Branch, Russian Academy of Sciences

References

  1. Бездетко Н.В. Цитиколин: новое об известном. Международный неврологический журнал. 2015; 4: 90-4
  2. Веселова О.Ф., Крысенко Л.В., Макарова М.В. и др. Вопросы современной науки: монография. М.: Интернаука, 2017; 22.
  3. Государственный реестр лекарственных средств [Электронный ресурс]. URL: https://grls.rosminzdrav.ru/grls.aspx
  4. Громова О.А., Торшин И.Ю., Стаховская Л.В. и др. Опыт применения мексидола в неврологической практике. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018; 118 (10): 97-107 DOI. 10.17116/jnevro201811810197
  5. Камчатнов П.Р. Коррекция когнитивных и эмоциональных расстройств у больных артериальной гипертонией. Русский медицинский журнал. 2019; 7: 28-9
  6. Краснов В.С. Актовегин в терапии когнитивных нарушений у пациентов, перенесших новую коронавирусную инфекцию COVID-19 (опыт клинических наблюдений). Эффективная фармакотерапия. 2021; 17 (6): 8-12 doi: 10.33978/2307-3586-2021-17-6-8-12
  7. Кудлай Д.А., Широбоков Я.Е., Гладунова Е.П. и др. Диагностика COVID 19. Способы и проблемы обнаружения вируса SARSCoV-2 в условиях пандемии. Врач. 2020; 31 (8): 5-10. doi: 10.29296/25877305-2020-08-01
  8. Мазин П.В., Шешунов И.В., Мазина Н.К. Метааналитическая оценка клинической эффективности цитофлавина при неврологических заболеваниях. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017; 117 (3): 28-39 DOI. 10.17116/ jnevro20171173128-39
  9. Пизова Н.В., Пизов Н.А., Пизов А.В. Когнитивные нарушения у лиц, перенесших COVID-19. Медицинский совет. 2021; 4: 69-77 doi: 10.21518/2079-701X-2021-4-69-77
  10. Потупчик Т.В., Веселова О.Ф., Эверт Л.С. Фармакодинамические аспекты применения некоторых ноотропных средств при когнитивных нарушениях. Фарматека. 2014; 13: 90-5
  11. Чуканова Е.И., Чуканова А.С. Холина альфосцерат (делецит) как одно из направлений лечения когнитивных расстройств. Медицинский алфавит. 2016; 14: 12-6
  12. Almeria M., Cejudo J.C., Sotoca J. et al. Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health. 2020; 9: 100163. DOI: 10.1016/j. bbih.2020.100163
  13. Alonso-Lana S., Marquie M., Ruiz A. et al. Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia. Front Aging Neurosci. 2020; 12: 588872. doi: 10.3389/fnagi.2020.588872
  14. Annweiler C., Bourgeais A., Faucon E. et al. Neurological, Cognitive, and Behavioral Disorders during COVID-19: The Nitric Oxide Track. J. Am Geriatr Soc. 2020; 68 (9): 1922-3. doi: 10.1111/jgs.16671
  15. Beaud V., Crottaz-Herbette S., Dunet V. et al. Pattern of cognitive deficits in severe COVID-19. J. Neurol Neurosurg Psychiatry. 2021; 92 (5): 567-8. doi: 10.1136/jnnp-2020-325173
  16. Delorme C., Paccoud O., Kas A. et al. COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings. CoCo-Neurosciences study group and COVID SMIT PSL study group. Eur J. Neurol. 2020; 27 (12): 2651-7. doi: 10.1111/ene.14478
  17. El H.M., Altintas E., Chapelet G. et al. High depression and anxiety in people with Alzheimer’s disease living in retirement homes during the COVID-19 crisis. Psychiatry Res. 2020; 291: 113294. doi: 10.1016/j.psychres.2020.113294
  18. Helms J., Kremer S., Merdji H. et al. Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients. Crit Care. 2020; 24 (1): 491. doi: 10.1186/s13054-020-03200-1
  19. Heneka M.T., Golenbock D., Latz E. et al. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020; 12 (1): 69. doi: 10.1186/s13195-020-00640-3
  20. Malkova A., Kudlay D., Kudryavtsev I. et al. Immunogenetic Predictors of Severe COVID-19. Vaccines. 2021; 9: 211. doi: 10.3390/vaccines9030211
  21. Miners S., Kehoe P.G., Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimers Res Ther. 2020; 12 (1): 170. DOI: 10.1186/ s13195-020-00744-w
  22. Negrini F., Ferrario I., Mazziotti D. et al. Neuropsychological Features of Severe Hospitalized Coronavirus Disease 2019 Patients at Clinical Stability and Clues for Postacute Rehabilitation. Arch Phys Med Rehabil. 2021; 102 (1): 155-8. doi: 10.1016/j.apmr.2020.09.376
  23. Riordan P., Stika M., Goldberg J. et al. COVID-19 and clinical neuropsychology: A review of neuropsychological literature on acute and chronic pulmonary disease. Clin Neuropsychol. 2020; 34 (7-8): 1480-97. doi: 10.1080/13854046.2020.1810325
  24. Sepilveda-Loyola W., Rodriguez-Sanchez I., Perez-Rodriguez P. et al. Impact of Social Isolation Due to COVID-19 on Health in Older People: Mental and Physical Effects and Recommendations. J. Nutr Health Aging. 2020; 24 (9): 938-47. doi: 10.1007/s12603-020-1469-2
  25. Serrano-Castro P.J., Estivill-Torris G., Cabezudo-Garcia P. et al. Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? Neurologia. 2020; 35 (4): 245-51. DOI: 10.1016/j. nrl.2020.04.002
  26. Soltani Z.H., Gorji A., Ghadiri T.A Review on the Neurological Manifestations of COVID-19 Infection: a Mechanistic View. Mol Neurobiol. 2021; 58 (2): 536-49. doi: 10.1007/s12035-020-02149-0
  27. Stefano G.B., Ptacek R., Ptackova H. et al. Selective Neuronal Mitochondrial Targeting in SARS-CoV-2 Infection Affects Cognitive Processes to Induce ‘Brain Fog’ and Results in Behavioral Changes that Favor Viral Survival. Med Sci Monit. 2021; 27: e930886. doi: 10.12659/MSM.930886
  28. Varatharaj A., Thomas N., Ellul M.A. et al. CoroNerve Study Group. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020; 7 (10): 875-82. doi: 10.1016/S2215-0366(20)30287-X
  29. Xiong J., Lipsitz O., Nasri F. et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J. Affect Disord. 2020; 277: 55-64. doi: 10.1016/j.jad.2020.08.001
  30. Zhou H., Lu S., Chen J., et al. The landscape of cognitive function in recovered COVID-19 patients. JPsychiatrRes. 2020; 129: 98-102. DOI: 10.1016/j. jpsychires.2020.06.022
  31. Zhou J., Liu C., Sun Y. et al. Cognitive disorders associated with hospitalization of COVID-19: Results from an observational cohort study. Brain Behav Immun. 2021; 91: 383-92. doi: 10.1016/j.bbi.2020.10.019

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Russkiy Vrach Publishing House